6 Meridian’s Alexion Pharmaceuticals ALXN Stock Holding History

6 Meridian’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,321	Closed	-$243K	–	526
2021 Q2	$243K	Sell	1,321 -43	-3%	-$7.38K	0.02%	270
2021 Q1	$209K	Sell	1,364 -176	-11%	-$27.2K	0.02%	360
2020 Q4	$241K	Buy	+1,540	New	+$198K	0.02%	242

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

6 Meridian's ALXN Position: Q3 2021 in Review

6 Meridian sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,321 shares — an estimated $243K sold.

6 Meridian first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $243K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

6 Meridian reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
6 Meridian sold 1,321 Alexion Pharmaceuticals shares in Q3 2021, an estimated $243K.
6 Meridian first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
6 Meridian's Alexion Pharmaceuticals position peaked at $243K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on 6 Meridian's 13F filing for Q3 2021, filed 3 Nov 2021.